Skip to content

Effect of Intrauterine Injection of HCG on Pregnancy Outcome in Repeated Implantation Failure Patients

Effect of Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer on Clinical Pregnancy Outcome in Repeated Implantation Failure Patients

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02870855
Enrollment
0
Registered
2016-08-17
Start date
2017-07-28
Completion date
2018-01-01
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Repeated implantation failure(RIF) is a insurmountable bottleneck in assisted reproductive technology, many studies have considered that the cause of two-thirds of implant failure is the decreased endometrial receptivity. Human chorionic gonadotropin (hCG) is an early pre-plant signal molecule secreted by the embryo, it can promote endometrial proliferation, increase blood flow and promote embryonic adhesion and inhibit self-regulate apoptosis of trophoblast cells. Previous studies showed that: intrauterine injection of HCG before embryo transfer can improve clinical outcomes in IVF/Intracytoplasmic sperm injection(ICSI). But some studies found that the intrauterine injection of HCG can not significantly improve the success rate of blastocyst transfer, and the reason may be the intrauterine injection of HCG time is too late to significantly increase the implantation rate. Would ahead of intrauterine injection of HCG be more effective? Thus, the patients of repeated implantation frozen embryo cycle according to the random principle accepted two kinds of transplants ways: ①intrauterine injection of HCG before blastocyst transfer; ②blastocyst transfer. Try to understand whether intrauterine injection of HCG can significantly improve the clinical pregnancy rate of blastocyst transfer in repeated implantation failure patients.

Interventions

DRUGintrauterine injection of HCG

intrauterine injection of HCG berore blastocyst transfer

Sponsors

Reproductive & Genetic Hospital of CITIC-Xiangya
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* women with unexplained RIF(two to four previous embryo transfers without achieving pregnancy); * age\<36 years; * frozen embryo transfer cycles

Exclusion criteria

* polycystic ovary syndrome * uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus and uterine mediastinum) * intrauterine adhesions * endometriosis * adenomyosis * hydrosalpinx * uterine fibroids (submucosal fibroids, non-mucosal fibroids \> 4 cm and / or endometrial pressure) * thydroid dysfunction and hyperprolactinemia

Design outcomes

Primary

MeasureTime frameDescription
clinical pregnancy rateUntil 28 day after embryo transferredclinical pregnancy rate

Secondary

MeasureTime frameDescription
spontaneous abortion rateuntil 28 day after embryo transferredspontaneous abortion rate
ectopic pregnancy rateuntil 28 day after embryo transferredectopic pregnancy rate

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026